Kivizidiale (Timolol, Travoprost)

Timolol reduces aqueous humor production by blocking beta‑adrenergic receptors in the ciliary body, while travoprost increases uveoscleral outflow of aqueous humor as a prostaglandin F2α analog. Together they achieve a greater reduction in intra‑ocular pressure than either agent alone.

The dosing regimen for Kivizidiale is determined by the prescribing ophthalmologist based on the individual patient's condition, response, and tolerance. Patients should follow the specific instructions provided by their healthcare professional.

The safety of Kivizidiale in pregnancy or lactation has not been definitively established. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To request Kivizidiale, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kivizidiale combines a beta‑blocker and a prostaglandin analog, offering dual mechanisms—reduced aqueous production and increased outflow—whereas many single‑agent drops target only one pathway. This combination can provide stronger intra‑ocular pressure control for patients who need more than one class of therapy.

Kivizidiale eye drops should be stored at room temperature, below 25 °C, in the original container. Keep the bottle tightly closed, protect it from light and moisture, and discard any product that appears discolored or contains particles.

Kivizidiale is applied topically to the eye. The usual instruction is to instill one drop into the affected eye(s) as directed by the ophthalmologist, usually once daily in the evening, and to avoid touching the tip of the bottle to the eye or any surface.

Serious risks include severe allergic reactions, sudden worsening of glaucoma, systemic cardiovascular effects such as bradycardia or hypotension, and bronchospasm in patients with asthma or COPD. Patients should seek immediate medical attention if they experience chest pain, difficulty breathing, or rapid heart rate changes.

Kivizidiale is contraindicated in patients with known hypersensitivity to timolol, travoprost, or any excipients, as well as in individuals with severe asthma, chronic obstructive pulmonary disease, sinus bradycardia, or advanced heart block without a pacemaker. It should also be avoided in patients with active ocular infections.